Here are five updates on orthopedic regenerative medicine Becker's has reported on since Aug. 15: 

In the last 12 months, two orthobiologics companies have expanded their focus and rebranded.

HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.

A group of lawmakers wrote a letter to Robert Califf, MD, the U.S. FDA commissioner, pushing for stricter guidance for bone grafts in light of a recent spate of tuberculosis linked to orthopedic products.

The consensus on whether regenerative medicine is effective in sports medicine is still up in the air, according to Michael Ciccotti, MD, of Rothman Orthopaedic Institute in Philadelphia.

A Michigan woman died from tuberculosis linked to tainted bone graft, The Detroit News reported Aug, 18.

Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.

Here are five developments in orthopedic regenerative medicine since July 11.

Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26.

The CDC and FDA are investigating an outbreak of tuberculosis linked to recently recalled viable bone matrix material.

Ronald Hillock, MD, an adult joint reconstruction surgeon and musculoskeletal oncologist at Nevada Orthopedic & Spine Center in Las Vegas, connected with Becker's to answer, "Are orthobiologics overhyped?"

Gurtej Singh, MD, a physical medicine and rehabilitation physician, connected with Becker's to answer, "Are orthobiologics overhyped?"

Aziyo Biologics is recalling its viable bone matrix products after two patients were infected with Mycobacterium tuberculosis following surgeries, the orthobiologics company said July 13.

The first four surgeries using the EnFix RC fiber implant for rotator cuff repair were completed at Rush Oak Brook (Ill.) Surgery Center.

The Biden administration launched a program under the Advanced Research Projects Agency for Health focused on orthopedic tissue regeneration.

Here are five developments in orthobiologics to know since April 1:

Royal Biologics launched its Bio-Reign 3D bone graft substitute, the company said May 23.

Creative Medical Technology Holdings' StemSpine procedure was found to be effective in treating chronic lower back pain, according to a pilot study.

Bioventus sold its wound care segment to LifeNet Health, according to a May 10 news release.

OssDesign's Catalyst nanosynthetic bone graft has been used in 1,000 patients, the medtech company said May 9.